Transaction Details

Footnotes

Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 8, 2025, by and among Churchill Capital Corp X, a Delaware corporation now known as Infleqtion, Inc. ("Acquiror"), AH Merger Sub I, Inc., a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub I"), AH Merger Sub II, LLC, a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub II" and together with Merger Sub I, "Merger Subs") and ColdQuanta, Inc. (the "Company") pursuant to which (a) Merger Sub I was merged with and into the Company, and the Company continued as the surviving corporation and immediately thereafter, (b) the Company merged with and into Merger Sub II, and Merger Sub II became the surviving company and continued in existence as a wholly-owned subsidiary of Acquiror (collectively, the "Mergers"). In connection with the Mergers, Acquiror changed its name to Infleqtion, Inc. (the "Issuer"). | Represents shares of common stock of the Issuer issued upon conversion of the Company's Series C-1 preferred stock pursuant to the Mergers. | Held directly by Catalyzer Ventures, LP Fund I ("Catalyzer"). Dr. Johnson may be deemed to beneficially own shares held by Catalyzer by virtue of her voting power and investment power over such shares. | The shares vest on a monthly basis beginning on June 1, 2024 with respect to 1/36 of the total number of shares until such time as the option is 100% vested, subject to the continuous service of the Reporting Person as of each such date. | Pursuant to the Mergers, the legacy stock options of the Company were automatically converted into the right to receive stock options of the Issuer with the same terms and conditions.